閉塞性心不全における右心室血管相互作用. 低周波阻抗の重要性について
W G Kussmaul1, J A Altschuler, W H Matthai
1Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia.
Circulation
|September 1, 1993
まとめ
ニトロプロシドは,肺動脈の血動力学を変えることで,心不全における心臓の出力を改善します. 低用量では,阻力変化によってストロークの量を減少させることができ,高用量では,流れを改善し,電力需要を減らすことができます.
科学分野:
- 心臓病学 心臓病学
- ヘモダイナミクスは,
- 薬理学 薬理学とは
背景:
- 血管拡張剤は,充血性心不全の管理に不可欠です.
- 脈動性の高い右心室の液圧負荷に与える影響は大きい.
研究 の 目的:
- 肺動脈 (PA) 脈動性血動力学に対するニトロプルーシドの影響を,重度の結血性心不全の患者で調査する.
- 血液動力学的変化と心電量と脳卒中量の変化を相関させるため.
主な方法:
- 高精度圧力トランスデューサーとフロー速度プローブによる心臓キャセテリゼーションを15人の患者で実施した.
- グレードされたニトロプルスシド注入中のPA圧力とフローの継続的な記録.
- フォリエ変換を用いたPA阻力,水力,波反射指数の導出.
主要な成果:
- ニトロプルーシドの高用量投与により,心拍数が大幅に改善され,PA圧,抵抗,阻力,波反射が低下しました.
- 低用量では,低周波阻力変化によるPAの血液動力学が変化し,時には脳卒中の体積が減少しました.
- 第1ハーモニックインピデンスの変化は,低用量での脳卒中容量の変化と相関する.
結論:
- ニトロプロシドは,肺血管拡張を通して心不全における心室血管相互作用に影響します.
- 脈動性ヘモダイナミック特性を理解することは,心臓の出力に対するニトロプロシドの効果を評価するために不可欠です.
- 高い用量では,ニトロプロシドは,前向きの流れを改善し,水力発電の必要性を減らすことで利点を提供します.
さらに関連する動画
関連する概念動画
01:29Pathophysiology of Cardiac Performance
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
01:26Imbalances in Cardiac Output
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
01:20Mitral Regurgitation I: Introduction
Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
01:22Mitral Stenosis I: Introduction
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
01:27Heart Failure I: Introduction
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.